Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease

CompletedOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

November 21, 2017

Primary Completion Date

November 13, 2018

Study Completion Date

November 13, 2018

Conditions
Lung Diseases, Interstitial
Interventions
DRUG

Ipratropium Bromide

Single dose of 500 mcg Ipratropium nebulizer solution will be administered to all subjects via inhalation route using nebulizer for 10 minutes. Ipratropium bromide is a clear, colorless nebulizer solution available in white plastic ampoules.

PROCEDURE

Flexible Bronchoscopy/Biopsy

After biopsy samples required for diagnosis have been collected, additional one to two TBCB samples will be taken for this study. 3-5 endobronchial biopsy samples will be taken from up to 5 subjects to compare drug distribution in proximal and distal lung.

Trial Locations (1)

NW1 2PG

GSK Investigational Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

University College London Hospitals

OTHER

lead

GlaxoSmithKline

INDUSTRY

NCT03136120 - Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease | Biotech Hunter | Biotech Hunter